Literature DB >> 21350186

Animal models for the study of liver fibrosis: new insights from knockout mouse models.

Hiromitsu Hayashi1, Takao Sakai.   

Abstract

Fibrosis arises as part of a would-healing response that maintains organ structure and integrity following tissue damage but also contributes to a variety of human pathologies such as liver fibrosis. Liver fibrosis is an abnormal response of the liver to persistent injury with the excessive accumulation of collagenous extracellular matrices. Currently there is no effective treatment, and many patients end up with a progressive form of the disease, eventually requiring a liver transplant. The clarification of mechanisms underlying pathogenesis of liver fibrosis and the development of effective therapy are of clinical importance. Experimental animal models, in particular targeted gene knockouts (loss of function) in mice, have become a powerful resource to address the molecular mechanisms or significance of the targeted gene in hepatic functions and diseases. This review will focus on the recent advances in knowledge obtained from genetically engineered mice that provide novel insights into the pathophysiology of liver fibrosis.

Entities:  

Mesh:

Year:  2011        PMID: 21350186      PMCID: PMC3094136          DOI: 10.1152/ajpgi.00013.2011

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  120 in total

1.  Modeling liver fibrosis in rodents.

Authors:  Christothea Constandinou; Neil Henderson; John P Iredale
Journal:  Methods Mol Med       Date:  2005

Review 2.  Smad transcription factors.

Authors:  Joan Massagué; Joan Seoane; David Wotton
Journal:  Genes Dev       Date:  2005-12-01       Impact factor: 11.361

3.  Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.

Authors:  Liu Yang; Ramón Bataller; Jennyfer Dulyx; Thomas M Coffman; Pere Ginès; Richard A Rippe; David A Brenner
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

4.  Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.

Authors:  Sonja Hillebrandt; Hermann E Wasmuth; Ralf Weiskirchen; Claus Hellerbrand; Hildegard Keppeler; Alexa Werth; Ramin Schirin-Sokhan; Gabriele Wilkens; Andreas Geier; Johann Lorenzen; Jörg Köhl; Axel M Gressner; Siegfried Matern; Frank Lammert
Journal:  Nat Genet       Date:  2005-07-03       Impact factor: 38.330

5.  Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach.

Authors:  Alexandre Lautrette; Shunqiang Li; Rohia Alili; Susan W Sunnarborg; Martine Burtin; David C Lee; Gérard Friedlander; Fabiola Terzi
Journal:  Nat Med       Date:  2005-07-24       Impact factor: 53.440

6.  Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

Authors:  Boris Julien; Pascale Grenard; Fatima Teixeira-Clerc; Jeanne Tran Van Nhieu; Liying Li; Meliha Karsak; Andreas Zimmer; Ariane Mallat; Sophie Lotersztajn
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

7.  An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis.

Authors:  John G Lunz; Hirokazu Tsuji; Isao Nozaki; Noriko Murase; Anthony J Demetris
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Expression pattern of matrix metalloproteinases-13 in a rat model of alcoholic liver fibrosis.

Authors:  Sheng Yan; Ge-Min Chen; Chao-Hui Yu; Guo-Fang Zhu; You-Ming Li; Shu-Sen Zheng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2005-11

9.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 10.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

View more
  29 in total

1.  Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis.

Authors:  Moses T Bility; Liguo Zhang; Michael L Washburn; T Anthony Curtis; Grigoriy I Kovalev; Lishan Su
Journal:  Nat Protoc       Date:  2012-08-09       Impact factor: 13.491

2.  Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis.

Authors:  Suneetha Amara; Karina Lopez; Babak Banan; Sade-Kemi Brown; Margaret Whalen; Elbert Myles; Michael T Ivy; Terrance Johnson; Kevin L Schey; Venkataswarup Tiriveedhi
Journal:  Mol Immunol       Date:  2014-11-11       Impact factor: 4.407

3.  Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice.

Authors:  Fatemeh Momen-Heravi; Donna Catalano; Austin Talis; Gyongyi Szabo; Shashi Bala
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-14       Impact factor: 10.183

4.  Role of CTGF gene promoter methylation in the development of hepatic fibrosis.

Authors:  Cuicui Shi; Guangming Li; Yanyan Tong; Yilin Deng; Jiangao Fan
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

Review 5.  Experimental models of liver fibrosis.

Authors:  Sara Crespo Yanguas; Bruno Cogliati; Joost Willebrords; Michaël Maes; Isabelle Colle; Bert van den Bossche; Claudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Ferreira Alves; Isabelle Leclercq; Mathieu Vinken
Journal:  Arch Toxicol       Date:  2015-06-06       Impact factor: 5.153

6.  Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury.

Authors:  Shahrouz Ghafoory; Rohan Varshney; Tyler Robison; Karim Kouzbari; Sean Woolington; Brennah Murphy; Lijun Xia; Jasimuddin Ahamed
Journal:  Blood Adv       Date:  2018-03-13

Review 7.  Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.

Authors:  Bénédicte Delire; Peter Stärkel; Isabelle Leclercq
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

8.  Transforming growth factor-β-independent role of connective tissue growth factor in the development of liver fibrosis.

Authors:  Keiko Sakai; Safdar Jawaid; Takako Sasaki; George Bou-Gharios; Takao Sakai
Journal:  Am J Pathol       Date:  2014-08-07       Impact factor: 4.307

9.  Smad3 gene C-terminal phosphorylation site mutation exacerbates CCl4-induced hepatic fibrogenesis by promoting pSmad2L/C-mediated signaling transduction.

Authors:  Juan Yang; Yongfang Gong; Wenjing Xu; Lili Li; Zhenghao Shi; Qin Wang; Yinghao He; Chong Zhang; Chenchen Luo; Zhirui Fang; Yan Yang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-06-30       Impact factor: 3.000

Review 10.  Liver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response.

Authors:  Florent Duval; Jorge E Moreno-Cuevas; María Teresa González-Garza; Carmen Maldonado-Bernal; Delia Elva Cruz-Vega
Journal:  Int J Inflam       Date:  2015-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.